Nicotine metabolism mostly takes place inside the liver. As a result, when nicotine is administered with the GI program, it undergoes very first-pass metabolism from the liver, leading to a bioavailability of only about twenty%. This method inherently decreases the bioavailability of nicotine throughout the process and should lead to adverse GI res